These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 33797705)

  • 1. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
    Roy R; Alotaibi AA; Freedman MS
    CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
    Chaudhry BZ; Cohen JA; Conway DS
    Neurotherapeutics; 2017 Oct; 14(4):859-873. PubMed ID: 28812220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
    Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
    Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingosine 1-phosphate receptor modulators in multiple sclerosis.
    Subei AM; Cohen JA
    CNS Drugs; 2015 Jul; 29(7):565-75. PubMed ID: 26239599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.
    D'Ambrosio D; Freedman MS; Prinz J
    Ther Adv Chronic Dis; 2016 Jan; 7(1):18-33. PubMed ID: 26770667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A; Whichello C; Le HH; Kern DM; Fernandez GS; Turner V; Das A; Quaife M; Ross AP
    Patient; 2024 May; ():. PubMed ID: 38748388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases.
    Sankar Kar S; Gharai SR; Sahu SK; Ravichandiran V; Swain SP
    Curr Top Med Chem; 2024 Apr; ():. PubMed ID: 38676503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural determinants of sphingosine-1-phosphate receptor selectivity.
    Wunsch F; Nguyen TN; Wolber G; Bermudez M
    Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300387. PubMed ID: 37806764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.
    Yang X; Yan Y; Liu S; Wang Z; Feng X
    Front Pharmacol; 2024; 15():1376494. PubMed ID: 38846098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
    Chun J; Brinkmann V
    Discov Med; 2011 Sep; 12(64):213-28. PubMed ID: 21955849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.
    Coyle PK; Freedman MS; Cohen BA; Cree BAC; Markowitz CE
    Ann Clin Transl Neurol; 2024 Apr; 11(4):842-855. PubMed ID: 38366285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailable central nervous system disease-modifying therapies for multiple sclerosis.
    Hartung HP; Cree BAC; Barnett M; Meuth SG; Bar-Or A; Steinman L
    Front Immunol; 2023; 14():1290666. PubMed ID: 38162670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
    Vališ M; Achiron A; Hartung HP; Mareš J; Tichá V; Štourač P; Halusková S; Angelucci F; Pavelek Z
    Drugs R D; 2023 Dec; 23(4):331-338. PubMed ID: 37640862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis.
    Sanna K; Bruno A; Balletta S; Caioli S; Nencini M; Fresegna D; Guadalupi L; Dolcetti E; Azzolini F; Buttari F; Fantozzi R; Borrelli A; Stampanoni Bassi M; Gilio L; Lauritano G; Vanni V; De Vito F; Tartacca A; Mariani F; Rovella V; Musella A; Centonze D; Mandolesi G
    Front Immunol; 2024; 15():1416133. PubMed ID: 38911847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Siponimod: A Review in Secondary Progressive Multiple Sclerosis.
    Scott LJ
    CNS Drugs; 2020 Nov; 34(11):1191-1200. PubMed ID: 33108633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.
    Laiho A; Laitinen TM; Hartikainen P; Hartikainen JEK; Laitinen TP; Simula S
    Brain Behav; 2018 Feb; 8(2):e00925. PubMed ID: 29484274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis.
    Ong S; Kibbler J; Maxwell G; Steer J
    BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38171639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis.
    Bascuñana P; Möhle L; Brackhan M; Pahnke J
    Drugs R D; 2020 Sep; 20(3):197-207. PubMed ID: 32696271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.
    Hunter SF; Bowen JD; Reder AT
    CNS Drugs; 2016 Feb; 30(2):135-47. PubMed ID: 26715391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
    Guerrieri S; Rubin M; Gattuso I; Zanetta C; Genchi A; Preziosa P; Rocca MA; Filippi M; Moiola L
    J Neurol; 2024 Jun; 271(6):3678-3681. PubMed ID: 38564055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.